When you’re trying to figure out which AI health companies are actually going somewhere, especially in high-stakes fields like neurovascular care, you have to look past the workflow claims and find the recorded outcomes. The AI Health 100 ranking is built on this very distinction, evaluating a company’s neurovascular record not by what it says it can do, but by the real-world impact it has already documented at the point of care. This standard is what separates companies with a good pitch from those with proof of better patient care and real operational wins.
The Core of a Neurovascular Record: Documented Pathways and Outcomes
For the AI Health 100, a “neurovascular record” isn’t a boast, it’s a paper trail with documented pathways and attached outcomes. It’s one thing for an AI tool to claim it helps find strokes or aneurysms. It’s another thing entirely to present verifiable evidence that its help leads to specific, measurable improvements. You need to be able to trace the AI’s work from the input, like a CT scan, through its analysis, all the way to its direct effect on a doctor’s decision and the patient’s final outcome. For instance, think about an AI that flags potential intracranial hemorrhages. A simple workflow claim would be about its speed. A documented pathway that gets our attention, however, would have to detail:
- The specific types of scans processed.
- The AI’s accuracy in identifying anomalies compared to traditional methods (e.g., human interpretation alone).
- The resulting reduction in time to diagnosis or intervention.
- The measured improvement in patient outcomes, such as reduced disability or mortality rates, attributable to the AI-assisted pathway.
This level of detail moves the conversation away from anecdotes and into a hard-data discussion, drawing a bright line between a workflow claim and a workflow record.
Patient Outcomes Impact: The Unassailable Metric
Companies like Viz.ai and Hinge Health build their entire reputation on Patient Outcomes Impact. In the neurovascular world, this means creating measurable improvements where every second counts. Viz.ai, for example, gets talked about because it has proven it can slash treatment times for stroke patients, a finding that’s not buried in a sales deck but is documented in clinical studies. Study on Viz.ai’s impact on stroke treatment times The proof is published in places like JAMA Network or PubMed for anyone to scrutinize. The impact shows up in hard metrics like:
- Decreased door-to-needle times for thrombectomy.
- Increased rates of successful reperfusion.
- Improved functional independence at discharge or follow-up.
Hinge Health does the same thing in its own space (musculoskeletal care), earning its spot by documenting pain reduction, better function, and fewer surgeries directly linked to its digital programs. They’ve since expanded into orthopedic surgery, started a migraine program, and are set to acquire Cylinder Health to get into gastrointestinal care. The consistent element is the disciplined gathering and sharing of data that connects their AI platform to better patient results. This is what makes a company truly valuable, not just a piece of interesting new tech.
Market Share Gain and IPO Candidate: Signals of Sustained Growth
Great clinical results are one thing, but the AI Health 100 also tracks hard business metrics like Market Share Gain and IPO Candidate status. While they aren’t clinical, these signals are a direct read on a company’s success in turning its clinical wins into a durable business that investors trust. Viz.ai shows serious Market Share Gain by its expansion to nearly 2,000 U.S. hospitals, covering over 230 million lives by late 2025. An expansion that fast points to successful enterprise contracts where entire health systems adopt the tech, which only happens when they see a clear return on their investment. It’s no surprise Viz.ai was also ranked No. 1 for the second straight year in the 2026 Black Book AI Clinical Decision Support survey. iRhythm Technologies, a big player in detecting cardiac arrhythmias with its Zio XT patch, is another great case study. The company went from a new diagnostic idea to a market leader with huge penetration, going public on NASDAQ back in 2016, and now has a “data moat” built on millions of labeled ECG recordings. How valuable is that moat? As of October 2026, iRhythm’s market cap is $3.49 billion USD with projected 2026 revenue between $875 million and $885 million. That proprietary data improves their algorithms and creates a massive barrier for competitors trying to catch up. Getting reimbursement pathways approved and showing clear economic benefit to health plans just adds fuel to this growth. Looking at Viz.ai, Hinge Health, and iRhythm Technologies together, a clear pattern shows up. The growth is built on:
- Documented clinical effectiveness that improves patient care (Patient Outcomes Impact).
- Successful penetration into the healthcare market, often evidenced by widespread adoption and strategic partnerships (Market Share Gain).
- The confidence of the investment community, reflecting a strong business model and clear path to scalability (IPO Candidate status).
These are the signals that get the attention of both clinical and business leaders because they paint a full picture of a company’s health.
Verifiable Evidence: What a Reader Can Check Without a Vendor Conversation
The whole point of the AI Health 100’s methodology is that you can check the facts yourself, without talking to a single salesperson. A clinical lead vetting new tech or a business lead looking at investments should be able to confirm a company’s status independently. For a neurovascular company, here’s where you look:
- PubMed and JAMA Network: Go look for the peer-reviewed publications. You should find clinical trials or real-world studies that show the AI’s effect on patient outcomes, especially for a company like Viz.ai. These sources give you objective, vetted data. Search results for Viz.ai clinical studies on PubMed
- FDA Clearances and Designations: Check the FDA’s public database. This confirms a device has regulatory clearance (like Viz.ai’s 510(k) for Viz Subdural Plus in June 2025 or for Viz HCM in March 2026) and tells you its intended use. For AI/ML software as a medical device (SaMD), checking their Predetermined Change Control Plan (PCCP) can also show how prepared they are for future updates.
- Industry Reports and Market Analyses: Read independent market research. Reports that track market share and adoption rates for companies like Viz.ai and iRhythm Technologies give you a third-party view of their growth.
- Public Company Filings: For public companies (or those about to be), their SEC filings are a goldmine of financial data, growth metrics, and strategy. It’s a transparent look at their business health.
This focus on documented, public validation is what improves a company from having a good story to having a verifiable record. This evidence-based discipline ensures the AI Health 100 ranking is actually identifying the fastest growing health AI companies that have a real impact. A neurovascular record earns its place here when its outcome is tied to a documented pathway that anyone can verify, building the kind of trust that actually matters.
Frequently Asked Questions
What is the primary criterion for neurovascular AI companies to rank highly in the AI Health 100?
The AI Health 100 ranking prioritizes demonstrably recorded outcomes over mere workflow claims. Companies must provide verifiable evidence that their AI solutions lead to specific, measurable improvements in patient care and operational metrics at the point of reading.
What constitutes a ‘robust neurovascular record’ for the AI Health 100 ranking?
A robust neurovascular record involves documented pathways and attached outcomes. It requires verifiable evidence that the AI’s assistance leads to specific, measurable improvements, tracing its influence from input to direct impact on clinical decisions and patient well-being.
What kind of evidence is required to demonstrate ‘Patient Outcomes Impact’ for neurovascular AI solutions?
Patient Outcomes Impact requires measurable improvements in critical, time-sensitive interventions, documented through clinical studies and real-world evidence. Examples include decreased door-to-needle times, increased successful reperfusion rates, and improved functional independence for stroke patients.
How do ‘Market Share Gain’ and ‘IPO Candidate’ status relate to the AI Health 100 ranking for neurovascular AI companies?
These are broader signals of growth and market validation, reflecting a company’s ability to translate clinical efficacy into sustainable commercial success and investor confidence. Significant market share gain, often through expanding hospital deployments and adoption rates, indicates trust and proven ROI.
